Natalie S. Callander

15.9k citations

199 papers · 5.9k indexed · 1 hit paper · h-index 41

Impact in

Hematology top 0.1%
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
Oncology top 0.5%
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Bone health and treatments

Papers in

Hematology 154
- Multiple Myeloma Research and Treatments 129
- Hematopoietic Stem Cell Transplantation 18
- Acute Myeloid Leukemia Research 16
Oncology 89
- Cancer Treatment and Pharmacology 26
- Peptidase Inhibition and Analysis 19
- Neutropenia and Cancer Infections 13

Co-authors: S. Vincent Rajkumar Rafaël Fonseca Susanna Jacobus Philip R. Greipp Rafat Abonour David S. Siegel David H. Vesole Nissi Varki
Journals: Blood (66 papers)Journal of Clinical Oncology (24 papers)Biology of Blood and Marrow Transplantation (7 papers)Journal of the National Comprehensive Cancer Network (6 papers)British Journal of Haematology (5 papers)
Partner nations: United States Canada Germany

In The Last Decade

Natalie S. Callander

189 papers receiving 5.8k citations

Hit Papers

align trajectories log scale

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial 2009 · 673 citations

Peers

Countries citing papers authored by Natalie S. Callander

Since Specialization

Citations

This map shows the geographic impact of Natalie S. Callander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natalie S. Callander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natalie S. Callander more than expected).

Fields of papers citing papers by Natalie S. Callander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natalie S. Callander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natalie S. Callander. The network helps show where Natalie S. Callander may publish in the future.

Co-authors

The 25 scholars most cited alongside Natalie S. Callander, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Natalie S. Callander Line = papers co-authored together Natalie S. Callander links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Clinical Lymphoma Myeloma & Leukemia ·Ajai Chari, Susan Bal, Sikander Ailawadhi, Amrita Krishnan, Krina K. Patel, Jesús G. Berdeja, Alfred L. Garfall, Natalie S. Callander, Rahul Banerjee, Melissa Alsina, Ajay K. Nooka, Binod Dhakal, Cristina Gasparetto, Caitlin Costello	2025	0
2	Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation Blood ·Luciano J. Costa, Eva Medvedova, Binod Dhakal, Bhagirathbhai Dholaria, Smith Giri, Saurabh Chhabra, Susan Bal, Kelly Godby, Gayathri Ravi, Rebecca Silbermann, Natalie S. Callander	2024	1
3	Combination Regimens in MM Post Autologous Hematopoietic Cell Transplantation (AHCT) to Eliminate MRD Utilizing Iberdomide (COMMANDER): Results of Dose-Finding Component of a Phase 1b/2 Trial Blood ·Natalie S. Callander, Gayathri Ravi, Rebecca Silbermann, Zhubin Gahvari, Eva Medvedova, Bhagirathbhai Dholaria, Naresh Bumma, Doris K. Hansen, Everette M Colquette, Pamela Hardwick, Luciano J. Costa	2024	2
4	Infective endocarditis is rare in patients with hematologic malignancy and neutropenia Transplant Infectious Disease ·Michael Scolarici, Leigh Berman, Natalie S. Callander, Jeannina A. Smith, Christopher M. Saddler	2024	0
5	Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial Transplantation and Cellular Therapy ·Ehsan Malek, Jeries Kort, Leland Metheny, Pingfu Fu, Gen Li, Parameswaran Hari, Yvonne A. Efebera, Natalie S. Callander, Muzaffar H. Qazilbash, Sergio Giralt, Amrita Krishnan, Edward A. Stadtmauer, Hillard M. Lazarus	2024	1
6	PD1+TIGIT+2B4+KLRG1+ Cells Might Underlie T Cell Dysfunction in Patients Treated with BCMA-Directed Chimeric Antigen Receptor T Cell Therapy Transplantation and Cellular Therapy ·A. Mishra, Timothy M. Schmidt, Ella B. Martell, Alex S. Chen, Reyna Elvan Dogru, Peiman Hematti, Natalie S. Callander	2023	9
7	Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology Science Advances ·Nicholas J Hess, David P Turicek, Jeremiah Riendeau, Sean J. McIlwain, Emmanuel Contreras Guzman, Kalyan Nadiminti, Amy W. Hudson, Natalie S. Callander, Melissa C. Skala, Jenny E. Gumperz, Peiman Hematti, Christian M. Capitini	2023	17
8	Initial Results from a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination with WHG626, a Gamma-Secretase (GS) Inhibitor, in Patients with Relapsed and/or Refractory Multiple Myeloma Blood ·Fredrik Schjesvold, Andrew Spencer, Yaël C. Cohen, Enrique M. Ocio, Jordi López‐Pardo, Anna Maria Cafro, Natalie S. Callander, Jonathan L. Kaufman, Meera Mohan, Martin Wermke, Noriko Doki, Rebecca Kan, Karolina Kulec, Gina M. Trabucco, S. Ye, Romain Séchaud, Cornelia Quadt, Raghav Chawla, Marc S. Raab	2023	3
9	Update on the current and future use of CAR‐T to treat multiple myeloma European Journal Of Haematology ·Zhubin Gahvari, Matthew Brunner, Timothy M. Schmidt, Natalie S. Callander	2023	3
10	A Hyaluronan and Proteoglycan Link Protein 1 Matrikine: Role of Matrix Metalloproteinase 2 in Multiple Myeloma NF-κB Activation and Drug Resistance Molecular Cancer Research ·Christina Mark, Jay W. Warrick, Natalie S. Callander, Peiman Hematti, Shigeki Miyamoto	2022	11
11	Timelapse viability assay to detect division and death of primary multiple myeloma cells in response to drug treatments with single cell resolution Integrative Biology ·Christina Mark, Natalie S. Callander, Kenny Chng, Shigeki Miyamoto, Jay W. Warrick	2022	1
12	Outcomes of Hematopoietic Progenitor Cells Mobilization and Collection Following Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone Induction in Newly Diagnosed Multiple Myeloma Transplantation and Cellular Therapy ·Saurabh Chhabra, Nicole Watts, Rebecca Silbermann, Bhagirathbhai Dholaria, Timothy M. Schmidt, Susan Bal, Luciano J. Costa, Bicky Thapa, Binod Dhakal, Anita D’Souza, Eva Medvedova, Parameswaran Hari, Natalie S. Callander	2021	0
13	Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma Journal of Clinical Oncology ·Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai Dholaria, Timothy M. Schmidt, Kelly Godby, Rebecca Silbermann, Binod Dhakal, Susan Bal, Smith Giri, Anita D’Souza, Aric C. Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Hari, Natalie S. Callander	2021	146
14	Versican (VCAN) Proteolysis Predicts T-Cell Infiltration in Myeloma Bone Marrow Post- Autologous Stem Cell Transplant (ASCT) Blood ·Adam Pagenkopf, Binod Dhakal, Chelsea Hope, Athanasios Papadas, Michael G. Johnson, Bradley Nagel, Elena Kurudza, Samik Partha, Bianca Ruffolo, Catherine P. Leith, Shigeki Miyamoto, Peiman Hematti, Parameswaran Hari, Natalie S. Callander, Fotios Asimakopoulos	2017	1
15	Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma Cancer Immunology Research ·Jeffrey L. Jensen, Alexander L. Rakhmilevich, Erika Héninger, Aimee Teo Broman, Chelsea Hope, Funita Phan, Shigeki Miyamoto, Ιωάννα Μαρουλάκου, Natalie S. Callander, Peiman Hematti, Marta Chesi, P. Leif Bergsagel, Paul M. Sondel, Fotis Asimakopoulos	2015	22
16	A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation Biology of Blood and Marrow Transplantation ·Parameswaran Hari, Omar S. Aljitawi, Carlos Arce‐Lara, Rajneesh Nath, Natalie S. Callander, Gajanan Bhat, Lee F. Allen, Keith Stockerl‐Goldstein	2015	23
17	Bortezomib-Resistant Nuclear Factor-κB Activity in Multiple Myeloma Cells Molecular Cancer Research ·Stephanie Markovina, Natalie S. Callander, Shelby L. O’Connor, Jihoon Kim, Jae Werndli, Martha Raschko, Catherine P. Leith, Brad S. Kahl, KyungMann Kim, Shigeki Miyamoto	2008	118
18	Peripheral Blood Stem Cell Mobilization with Cyclophosphamide in Combination with G-CSF, GM-CSF, or Sequential GM-CSF/G-CSF in Non-Hodgkin's Lymphoma Patients: A Randomized Prospective Study Journal of Hematotherapy & Stem Cell Research ·Yair Gazitt, Natalie S. Callander, César O. Freytes, Paul Shaughnessy, Qun Liu, Tsuong-Wu Tsai, P A DeVore	2000	31
19	A phase I-II clinical trial with a combination of gemcitabine (GEMZAR) and paclitaxel (TAXOL) for the treatment of refractory multiple myeloma (MM) patients Blood ·Yair Gazitt, G. David Roodman, César O. Freytes, Paul Shaughnessy, Natalie S. Callander, Anne M. Traynor, Mace L. Rothenberg	2000	3
20	Successful PBSC Mobilization with High-Dose G-CSF for Patients Failing a First Round of Mobilization Journal of Hematotherapy ·Yair Gazitt, César O. Freytes, Natalie S. Callander, Tsuong-Wu Tsai, Melissa Alsina, Jeanne E. Anderson, Lisa M. Holle, Jose C Ruz, P A DeVore, Michael McGrath, G. P. West, Robert Alvarez, Willie Montgomery	1999	55

About Natalie S. Callander

Natalie S. Callander is a scholar working on Hematology, Oncology, Genetics, Microbiology and Molecular Biology, having authored 199 papers that have together received 5.9k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (129 papers), Protein Degradation and Inhibitors (52 papers), Cancer Treatment and Pharmacology (26 papers), Peptidase Inhibition and Analysis (19 papers), Hematopoietic Stem Cell Transplantation (18 papers), Chronic Lymphocytic Leukemia Research (18 papers), Acute Myeloid Leukemia Research (16 papers) and Neutropenia and Cancer Infections (13 papers). The work is most often cited by research in Hematology (4.0k citations), Oncology (2.8k citations), Genetics (716 citations), Internal Medicine (174 citations) and Molecular Biology (3.2k citations). Natalie S. Callander has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include S. Vincent Rajkumar, Rafaël Fonseca, Susanna Jacobus, Philip R. Greipp, Rafat Abonour, David S. Siegel, David H. Vesole, Nissi Varki, Peiman Hematti and Michael E. Williams. Their work appears in journals such as Blood, Journal of Clinical Oncology, Biology of Blood and Marrow Transplantation, Journal of the National Comprehensive Cancer Network and British Journal of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact